

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

November 10, 2024

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled **"USFDA Classifies Biocon Biologics' Biocon Park Site in Bengaluru, India as Voluntary Action Initiated (VAI)."**

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh
Nand

Digitally signed by
Akhilesh Nand
Date: 2024.11.10
14:28:04 +05'30'

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Encl: as above

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

USFDA Classifies Biocon Biologics' Biocon Park Site in Bengaluru, India as Voluntary Action Initiated (VAI)

Bengaluru, Karnataka, India, November 10, 2024

“The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics’ facilities at Biocon Park, Bengaluru, India, as Voluntary Action Indicated (VAI).

“This relates to the combined cGMP inspection and Pre-Licensing Inspection (PLI) conducted by the agency between July 15 – 26, 2024. The inspection scope had included six (6) separate Biologics manufacturing units comprising of four (4) Drug Substance and two (2) Drug Product manufacturing plants as well as five (5) Analytical Quality Control Laboratories, four (4) Microbiology Laboratories, and two (2) Warehouses.

“Biocon Biologics remains committed to global standards of Quality and Compliance.”

– *Company Spokesperson*